Reply  by Van Driest, Sara L. et al.
None of the mutations reported by Van Driest et al. (1) follow the
admitted nomenclature system, and because of this, in some cases it is
not possible to identify the exact place where the mutation occurs. For
example (Table 1, p. 1906 in their study), the SNPs 2, 23, 30, 34, and
35 cannot be positioned in the reference sequence (it seems to be the
GI:2920822, even though it is not mentioned in the report) because
the investigators only give the amino acid number, and never the
nucleotide. The description of the nucleotide change in essential
because the genetic code is degenerated.
Also, with the use of an equivocal nomenclature system, the
same mutation may be reported in two or more different ways. We
believe that Van Driest et al. consider as novel—because of a
nomenclature error—mutations that have been previously de-
scribed. For example, they refer the SNP 43 as “ins aa G1041fs”;
in this case, it is impossible to determine where the muta-
tion occurs, because the number of the nucleotide where aa is
inserted is not given, but we believe it could correspond to
g.20025_20026insAA T1042fs described by Niimura et al. (6).
The same occurs with the SNPs 8 described by Erdmann et al. (7).
Finally, we have detected similar pitfalls in other published studies
on cardiomyopathies. Because of this, we would like to see an increase
in the quality of the genetic information published on cardiomyopa-
thies by employing the standard mutations’ nomenclature.
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REPLY
In their letter to the editor, Hermida and colleagues illuminate an
issue of ever-increasing importance not only to pathogenetic
studies involving hypertrophic cardiomyopathy (HCM), but for
genomics research as a whole. Their letter calls for standardization
of the format for mutation nomenclature to previously published
recommendations (1,2). Indeed, our laboratory has conformed to
alternate published recommendations (3), and a perusal of the
HCM mutation literature quickly reveals that each laboratory has
developed its own style for mutation reporting.
The pitfalls associated with mutation-formatting inconsisten-
cies are illustrated in our own study (4), where owing to inconsis-
tencies in published mutation nomenclature, three previously
reported mutations in MYBPC3 were mistakenly reported as
novel. The K811del in exon 25 was previously annotated as “exon
25 deletion 3 bp codon 811–815” (5). Exon 13, del c, D389 fs/15
was previously reported as “exon 14 del of c at nt 1200” (6). Finally,
exon 29, ins aa, G1041 fs/5 was previously reported as “Ins
AA1042” (7), and “exon 30, ins of AA at nt 3156” (6). Certainly,
standardization of format as well as nucleotide and exon number-
ing in future publication will enhance data accuracy. However,
several obstacles exist to the implementation of such standardiza-
tion. Nomenclature schemes must be acceptable and, ideally,
required uniformly by all publications. More importantly, any
recognized scheme must be useful for colleagues with diverse
research objectives including linkage analysis, candidate gene
screening, functional characterization, and genetic counseling.
Furthermore, to enable the amalgamation of past mutation data
with current and future discoveries including alternatively spliced
transcripts, large-scale sequence variants, and changing “wild-type”
genetic sequences, a dynamic compendium of sequence data is
required. Indeed, this has been attempted at the genome level with the
National Center for Biotechnology Information database (8), and
tailored specifically for HCM by the Familial HCMDNAMutation
Database (9). Continued submission to, and support of, these re-
sources will enable correlation of the vast data forthcoming with the
foundational groundwork provided by published works. The request for
standardization is much appreciated and has our complete endorsement.
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Effect of Two Different Neuroprotection
Systems on Microembolization During
Carotid Artery Stenting
After reading the study titled “Effect to Two Different Neuropro-
tection Systems on Microembolization During Carotid Artery
Stenting” by Schmidt et al. (1) in the Journal and after having an
extensive experience with a system that holds several similarities
with the MO.MA device (Invatec s.r.l., Roncadelle, Italy), I can
make the following comments.
The investigators stated that 71% of their patients had microem-
bolic signals (MESs) after balloon dilation of the stent; MESs during
stent placement and balloon dilation were more than six times higher
than during wire passage. This latter observation suggests that
antegrade flow was still present using the MO.MA device.
The utilization of balloon occlusion of the common carotid
artery (CCA) and external carotid artery (ECA) and the descrip-
tion of continuous MESs during carotid artery stenting (CAS)
using a filter device was reported earlier by us (2). The researchers
did not reference this original study.
Using occlusion of the CCA and ECA, we experienced, as did
Schmidt et al. (1), that MESs were still present; we attributed
them to antegrade flow through branches not occluded by the
balloon. The other potential explanation is a Venturi effect of the
circle of Willis suctioning from the column of stagnant flow in the
internal carotid artery after balloon occlusion.
Finally, owing to the above-mentioned findings, we added flow
reversed to the occlusion of the CCA and ECA.
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REPLY
Dr. Parodi mentions his experience with a similar protection
device, the PAES (Parodi antiembolism system) (1). Because of
the requirement of brevity of our study (2), the comparative
technical discussion of both systems (MO.MA vs. PAES) was not
possible. An advantage of the PAES over the MO.MA system
could be the potential continuous retrograde flow through the
target lesion during the intervention. Establishment of a continu-
ous retrograde flow in the internal carotid artery using this concept
has been demonstrated in an animal model (3). However, there are
no scientific data demonstrating and quantifying that, during the
critical phases of stent placement, delivery and postdilation of the
PAES permits an effective retrograde flow in humans. Dr. Parodi
mentioned in his study (1) the use of this protection device in nine
patients. Transcranial Doppler monitoring revealed no microem-
bolic signals (MESs) during clamping of the common carotid
artery in these patients. In our study, using the MO.MA system
there was also a considerable number of subjects (48% of 21
patients) showing no MESs during stent deployment and during
balloon dilation (29% of 21 patients). It is regrettable that a
controlled multicenter registry, showing the safety and feasibility
of the PAES, as it has been conducted recently using the MO.MA
system (4), is not yet available. A randomized comparison between
the PAES and MO.MA device using transcranial Doppler with
detection of MESs would be of interest.
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